[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …
tomography (PET) is emerging to become a reference imaging tool for the staging and …
[HTML][HTML] Optimizing PSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer. A systematic review and meta-analysis
FE von Eyben, G Bauman, R von Eyben… - International Journal of …, 2020 - mdpi.com
The aim of the review was to evaluate patient and treatment characteristics for patients with
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …
Computer-aided design of lasso-like self-assembling anticancer peptides with multiple functions for targeted self-delivery and cancer treatments
P Pei, L Chen, R Fan, XR Zhou, S Feng, H Liu, Q Guo… - ACS …, 2022 - ACS Publications
Anticancer peptides are promising drug candidates for cancer treatment, but the short
circulation time and low delivery efficiency limit their clinical applications. Herein, we …
circulation time and low delivery efficiency limit their clinical applications. Herein, we …
Is 18F-FDG PET needed to assess 177Lu-PSMA therapy eligibility? A VISION-like, single-center analysis
R Seifert, T Telli, B Hadaschik, WP Fendler… - Journal of Nuclear …, 2023 - Soc Nuclear Med
18F-FDG and prostate-specific membrane antigen (PSMA) PET have been used to assess
eligibility for PSMA-targeted therapy by some centers. However, it remains unclear whether …
eligibility for PSMA-targeted therapy by some centers. However, it remains unclear whether …
[HTML][HTML] Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET …
K Kessel, R Seifert, M Weckesser… - Annals of Nuclear …, 2022 - Springer
Introduction Fibroblast activation protein (FAP) has been recently presented as new imaging
target for malignant diseases and offers high contrast to surrounding normal tissue. FAP …
target for malignant diseases and offers high contrast to surrounding normal tissue. FAP …
[HTML][HTML] Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
F Khreish, K Ribbat, M Bartholomä, S Maus, T Stemler… - Cancers, 2021 - mdpi.com
Simple Summary Prostate-specific membrane antigen (PSMA) is regularly overexpressed in
prostate cancer cells. Radioligand therapy (RLT) targeting PSMA has shown impressive …
prostate cancer cells. Radioligand therapy (RLT) targeting PSMA has shown impressive …
[HTML][HTML] The Potential of PSMA as a Vascular Target in TNBC
A Heesch, L Ortmanns, J Maurer, E Stickeler… - Cells, 2023 - mdpi.com
Recent studies proving prostate-specific membrane antigen (PSMA) expression on triple-
negative breast cancer (TNBC) cells and adjacent endothelial cells suggest PSMA as a …
negative breast cancer (TNBC) cells and adjacent endothelial cells suggest PSMA as a …
[HTML][HTML] Evolving castration resistance and prostate specific membrane antigen expression: implications for patient management
K Kessel, C Bernemann, M Bögemann, K Rahbar - Cancers, 2021 - mdpi.com
Simple Summary This review is a summary of recent findings on the role of prostate-specific
membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC) and …
membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC) and …
Standardized PSMA-PET Imaging of Advanced Prostate Cancer
Imaging of advanced prostate cancer is a challenging task, as it requires longitudinal
characterization of disease extent in a standardized way to enable appropriate treatment …
characterization of disease extent in a standardized way to enable appropriate treatment …
[HTML][HTML] Prostate Cancer Theranostics With 177Lu-PSMA
H Ahmadzadehfar, R Seifert, A Afshar-Oromieh… - Seminars in nuclear …, 2024 - Elsevier
This review paper highlights the transformative role of PSMA-targeted diagnostics and
therapy in prostate cancer management, particularly focusing on 177 Lu-PSMA-617 …
therapy in prostate cancer management, particularly focusing on 177 Lu-PSMA-617 …